Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease

Next Previous
Trial Profile

Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy; Hepatic fibrosis; Liver cirrhosis
  • Focus Therapeutic Use

Most Recent Events

  • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
  • 25 Sep 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
  • 25 Sep 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top